Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation

Także dostęne w

Bleeding (hemorrhage) into the fluid-producing cavities (ventricles) of the brain is a serious complication of premature birth. Large hemorrhages may result in fluid building up under pressure, progressively enlarging the brain and head. Current treatment approaches, including the insertion of a valve drainage system (shunt) are fraught with problems. Acetazolamide and furosemide, two drugs with diuretic action, reduce the production of fluid in the ventricles of the brain and have been proposed as safe treatments to treat dilatation of the ventricles after intraventricular hemorrhage in newborn infants. When compared with standard treatment, diuretic therapy was found not to reduce the need for shunt surgery. Diuretic drugs are neither safe nor effective in treating ventricular dilatation in infants with intraventricular hemorrhage.

Wprowadzenie

Intraventricular hemorrhage remains a serious complication of premature birth and post-hemorrhagic hydrocephalus still has no satisfactory treatment. Acetazolamide and furosemide, which both reduce the production of cerebrospinal fluid, have been suggested as non-invasive therapies to reduce hydrocephalus and the need for ventriculo-peritoneal (V-P) shunting.

Cele

To determine the effect of acetazolamide and furosemide on shunt dependence and other complications in infants developing post-hemorrhagic ventricular dilatation.

Metody wyszukiwania badań

Searches were performed of electronic databases (MEDLINE from 1966, EMBASE from 1974 and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library). PubMed was searched on April 18, 2007 and Issue 2, 2007 of The Cochrane Library was searched.

Kryteria doboru badań

Randomised, or quasi-randomised trials, of acetazolamide and/or furosemide compared with standard therapy in infants with IVH or post-hemorrhagic ventricular dilatation

Zbieranie i analiza danych

Data were extracted independently by each author and were analysed by the standard methods of the Cochrane Collaboration using relative risk (RR) and risk difference (RD), a fixed effect model and sensitivity analyses where appropriate.

Główne wyniki

There were two eligible trials: one randomized 16 infants and the other 177 infants. Neither study showed a decreased risk for V-P shunt or for V-P shunt or death associated with acetazolamide and furosemide therapy. The larger trial showed that acetazolamide and furosemide treatment resulted in a borderline increase in the risk for motor impairment at one year (RR 1.27, 95% CI 1.02 - 1.58; RD 0.16, 95% CI 0.02 - 0.31), but did not significantly affect the risk for the combined outcome of delay, disability or motor impairment among survivors, or the risk of the combined outcome of death, delay, disability or impairment at one year. The larger trial showed that diuretic treatment increased the risk for nephrocalcinosis (RR 5.31, 95% CI 1.90 - 14.84; RD 0.19, 95% CI 0.09 - 0.29); meta-analysis confirmed this result.

Wnioski autorów

Acetazolamide and furosemide therapy is neither effective nor safe in treating post-hemorrhagic ventricular dilatation. Acetazolamide and furosemide cannot be recommended as therapy for post hemorrhagic hydrocephalus.

Cytowanie
Whitelaw A, Brion LP, Kennedy CR, Odd D. Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD002270. DOI: 10.1002/14651858.CD002270.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj